biotech · Recurrent Head and Neck Cancer · Metastatic Head and Neck Cancer · PDSB
PDS Biotechnology
PDS Biotechnology Corp
PDS Biotechnology is a biotech organization headquartered in Princeton, USA. It trades on NYSE under ticker PDSB. Primary therapeutic focus areas include Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, H
Princeton, USA HQ
2005 Founded
32 Employees
Public company Type
PDSB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Princeton, USA
- Founded
- 2005
- Employees
- 32
- Programs
- 3
- Drugs
- 5
- Patents
- 11
Pembrolizumab (KEYTRUDA®) and PDS0101
Phase 2 · other · Metastatic Head and Neck Cancer
Pembrolizumab (KEYTRUDA®) and PDS0101 for Metastatic Head and Neck Cancer is a Phase 2 program (other) at PDS Biotechnology Corp with 1 ClinicalTrials.gov record(s).
Internal code PDS0101-HNC-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- PDS Biotechnology Corp
- Phase
- Phase 2
- Modality
- other
- Indication
- Metastatic Head and Neck Cancer
- Status
- completed
- Trials
- 1